Twitter Beğeni Hilesi

Underexpression of the metabolic enzyme SDH is a common and adverse #epigenetic modulating feature in ccRCC according to findings from Lurie Cancer Center’s Niraj Shenoy, MD, PhD, MS, published in PNASNews news.feinberg.northwestern.edu/2021/10/study-… via Northwestern Feinberg School of Medicine #kidneycancer

Feinberg has been selected as the home of the Journal of Clinical Investigation (Journal of Clinical Investigation) for its next five-year term, and Elizabeth McNally, MD, PhD, will serve as the journal’s next editor-in-chief. spr.ly/6015JvVXN

Welcome to new faculty ⁦Lurie Cancer Center⁩ Dr Niraj K. Shenoy—GU Oncologist, cancer biologist, and Dir of kidney cancer research. Enjoyed learning about his journey and his research. If you see him in the hallways give him our warm purple welcome ⁦June M⁩

.Daniel Brat, MD, PhD, MD, PhD, chair of Northwestern Pathology and a member of Lurie Cancer Center, has been heavily involved in the process of moving molecular genetic #biomarkers for #glioma from the lab to clinical practice. Read more: news.feinberg.northwestern.edu/2022/03/pathol… via Northwestern Feinberg School of Medicine #neuropath

The seven priority areas in President Biden’s Cancer Moonshot 2.0 initiative.

Small but mighty! This is a video of a killer T cell of the immune system destroying a monstrous ovarian cancer cell. I recently captured this data on a spinning disc confocal microscope.

Thank you so much, Lynne Elmore. It was great having you here. Could not be more grateful to ACS Research for all the support!

Congratulations to Lurie Cancer Center’s Rebecca Luchtel, PhD, on receiving a 2023 ASH Scholar Award! Learn more about this prestigious research award at: hematology.org/newsroom/press… #ASHKudos

Thank you so much, Lynne! It was great connecting as always!

Does the addition of ipilimumab to standard-dose nivolumab safely improve clinical outcomes in patients with advanced cancers other than melanoma? Read the findings from Lurie Cancer Center investigators Niraj Shenoy, MD, PhD, MS and Anthony Serritella in JAMA Oncology jamanetwork.com/journals/jamao…

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma jamanetwork.com/journals/jamao…

Important analysis to inform benefit:risk assessment for patients!

A meta-analysis from Niraj Shenoy, MD, PhD, MS in JAMA Oncology revealed that in advanced cancers other than melanoma, the addition of ipilimumab to standard-dose nivolumab was not associated with clinically meaningful improvement. news.feinberg.northwestern.edu/2023/09/21/com… Anthony Serritella

(don't be scared of lining BMS pockets with nivo/ipi even if the level of evidence over nivo->salvage nivo/ipi is: trust me yo)

While the LMIC exploitation component is perhaps debatable (if one considers the flawed argument of local SoC), that the knowingly inferior control arms constitute a mockery of science is not.